Low Dose Naltrexone - Simple, Cheap, Non-Toxic Cancer Treatment

Learn about Low Dose Naltrexone (LDN) as a repurposed cancer treatment through this 21-minute medical discussion featuring Professor of Oncology Angus Dalgleish. Discover how naltrexone, originally designed to block opioid receptors for addiction treatment, shows promising anticancer properties when administered at very low doses. Explore three key mechanisms through which LDN may influence cancer progression: antagonism of toll-like receptors leading to IL-6 suppression, modulation of immune function, and direct inhibition of cancer cell signaling pathways including pro-apoptotic pathway priming. Examine the growing body of anecdotal evidence supporting LDN's effectiveness in cancer treatment and understand why this simple, inexpensive, and non-toxic approach remains largely overlooked in mainstream oncology. Gain insights into the broader challenges facing medical innovation, including restrictions on prescribing authority, limitations in medical education that discourage creative thinking, and barriers that prevent healthcare professionals from fully applying their knowledge to help patients. Access supporting research materials and clinical evidence through referenced studies and the LDN Research Trust resources to deepen your understanding of this emerging therapeutic approach.